Head to Head Survey: Janux Therapeutics (NASDAQ:JANX) & Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Nektar Therapeutics and Janux Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Janux Therapeutics	N/A	-11.89%	-11.13%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Nektar Therapeutics and Janux Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1	2	9	1	2.77
Janux Therapeutics	2	2	10	1	2.67

Nektar Therapeutics presently has a consensus target price of $141.50, suggesting a potential upside of 94.53%. Janux Therapeutics has a consensus target price of $36.46, suggesting a potential upside of 85.08%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Nektar Therapeutics is more favorable than Janux Therapeutics.

Insider & Institutional Ownership

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Nektar Therapeutics and Janux Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$54.59 million	45.50	-$164.08 million	($6.70)	-10.86
Janux Therapeutics	$24.00 million	50.18	-$113.62 million	($1.64)	-12.01

Janux Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500.

Summary

Janux Therapeutics beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.